WINDLAS

- Audio recording of the Investor/Analyst conference call for Q2 & H1 ended September 30, 2026, has been made available on the company website. - The written transcript of the call will be submitted to the stock exchanges in due course.

- Q2 FY27 Revenue from operations grew 19% YoY to ₹264 Cr. - Adjusted EBITDA increased 20% YoY to ₹36 Cr (margin 13.7%); Adjusted PAT rose 29% YoY to ₹25 Cr. - Commercialized Plant-6 in September 2026 and secured EUGMP certification for Plant-4 and Plant-5. - Maintained net debt-free balance sheet with ₹223 Cr in net liquidity.

- Mr. Ashok Kumar Windlass resigned as Whole-time Director and Director w.e.f. November 5, 2026, as part of succession planning. - Appointed as Founder President (Senior Management Personnel) w.e.f. November 6, 2026, at an annual remuneration of ₹1.56 Cr. - Managing Director Mr. Hitesh Windlass appointed as Chairman of the Board.

Q2 FY27 Standalone Revenue ₹263.91Cr vs ₹222.40Cr (▲18.7% YoY) EBITDA ₹29.37Cr vs ₹28.56Cr (▲2.8% YoY) PAT ₹18.05Cr vs ₹17.80Cr (▲1.4% YoY) EBITDA Margin 11.1% vs 12.8% (▼171bps)

Windlas Biotech Limited reported Q2 FY27 revenue of Rs. 264 crore, marking a 19% YoY growth and its 15th consecutive quarter of record revenue. - H1 FY27 revenue crossed Rs. 500 crore for the first time, reaching Rs. 512 crore (18% YoY growth). - Adjusted H1 FY27 EBITDA stood at Rs. 70 crore (up 23% YoY) and Adjusted PAT stood at Rs. 50 crore (up 33% YoY). - Commercialized Plant-6 in September 2026 and received EU GMP certification for Plant-4 and Plant-5. - Closed the half-year with a net liquidity of Rs. 223 crore and remaining net debt free.

New Filing detected. See link for details.